Trial Profile
Open-Label Extension Study of 23 mg Donepezil SR in Patients With Moderate to Severe Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Nov 2021
Price :
$35
*
At a glance
- Drugs Donepezil (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Eisai Inc
- 04 Aug 2017 New trial record